U.S. Department of Health and Human Services
Griffin Rodgers

 Contact Info

Tel: 301-496-0001
Email: griffin.rodgers@nih.gov

 Select Experience

  • M.B.A.Johns Hopkins University2005
  • M.D.Brown University1979
  • M.M.Sc.Brown University1979
  • Sc.B.Brown University1976

 Related Links


 Director's Biography

View Dr. Rodgers' Director's Biography.​

Griffin P. Rodgers, M.D., M.A.C.P.

Director, Office of the Director​
Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology Section, Molecular and Clinical Hematology Branch

Specialties: Molecular Biology/Biochemistry, Chemistry/Chemical Biology, Genetics/Genomics, Hematology​​​

Griffin P. Rodgers, M.D., M.A.C.P

Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology SectionMolecular and Clinical Hematology Branch
Director, Office of the Director
  • Chemistry/Chemical Biology
  • Genetics/Genomics
  • Hematology
  • Molecular Biology/Biochemistry
Research Summary/In Plain Language

Research in Plain Language

Dr. Rodgers conducts research on human blood diseases.  In one area of his research, Dr. Rodgers studies blood cells.  He develops methods that scientists can use to study how blood cells are formed.  This helps scientists develop medicine and other treatments for other blood diseases.

He also studies molecules and cells in people with blood diseases.  He looks for differences in how genes influence mature red blood cells and those that are still growing, and develops tests to measure and describe the level and severity of disease.  Dr. Rodgers looks for ways to move these research findings quickly from the lab to the clinic for further testing.

In a second area of his research, Dr. Rodgers develops therapies for blood diseases.  His work helped to create a new medicine to treat a genetic blood disorder called sickle cell anemia.  This medicine, called hydroxyurea, was the first medicine approved by the Food and Drug Administration (FDA) to treat this disease.  Research shows that people who have this disease and take this medicine at the recommended dose have higher survival rates than people who do not take the recommended dose, or who take the recommended dose and do not respond to the treatment.

Another new treatment involves the transplant of blood stem cells.  Transplanting these cells reversed sickle cell disease in more than 50 adults.  More than half of these adults were able to stop anti-rejection medications one year after the transplant. Meaning that these adults were able to achieve what is called “stable mixed donor chimerism,” a condition in which a person has two types of cells in their blood—their own cells and cells derived from the donor’s stem cells—with different DNA. The results of this study could help a wider range of people access to this type of treatment.  The results were repeated in 12 adult patients at the University of Illinois, and in 9 children with sickle cell anemia who were being treated at the University of Calgary.